Allogenic mitochondria transfer improves cardiac function in iPS-cell-differentiated cardiomyocytes of a patient with Barth syndrome
Open Access
- 24 June 2025
- journal article
- research article
- Published by Springer Nature in Experimental & Molecular Medicine
- Vol. 57 (6) , 1260-1271
Abstract
Barth syndrome (BTHS) is an ultrarare, infantile-onset, X-linked recessive mitochondrial disorder that primarily affects males, owing to mutations in TAFAZZIN, which catalyzes the remodeling of cardiolipin, a mitochondrial phospholipid required for oxidative phosphorylation. Mitochondrial transplantation is a novel technique to treat mitochondrial dysfunction by delivering healthy mitochondria to diseased cells or tissues. Here we explored the possibility of using stem-cell-derived cardiomyocytes as a source of mitochondrial transplantation to treat BTHS. We established induced pluripotent stem (iPS) cells from healthy individuals and from patients with BTHS and differentiated them into cardiomyocytes. The iPS-cell-differentiated cardiomyocytes (CMs) derived from patients with BTHS exhibited less expression of cardiomyocytes markers, such as α-SA, cTnT and cTnI, and smaller cell size than normal iPS-cell-derived CMs. Multielectrode array analysis revealed that BTHS CMs exhibited shorter beat period and longer field potential duration than normal CMs. In addition, mitochondrial morphology and function were impaired and mitophagy was decreased in BTHS CMs compared with normal CMs. Transplantation of mitochondria isolated from normal CMs induced mitophagy in BTHS CMs, mitigated mitochondrial dysfunction and promoted mitochondrial biogenesis. Furthermore, mitochondrial transplantation stimulated cardiac maturation and alleviated cardiac arrhythmia of BTHS CMs. These results suggest that normal CMs are useful for allogeneic transplantation in the treatment of mitochondrial diseases, including BTHS.Keywords
Funding Information
- National Research Foundation of Korea (NRF-RS-2023-00208466)
- Pusan National University Hospital (30-2021-000, 30-2021-000)
- Korea Health Industry Development Institute (HI19C1085)
This publication has 59 references indexed in Scilit:
- Mitochondrial transplantation protects against sepsis-induced myocardial dysfunction by modulating mitochondrial biogenesis and fission/fusion and inflammatory responseMolecular Biology Reports, 2022
- Clinical presentation and natural history of Barth Syndrome: An overviewJournal of Inherited Metabolic Disease, 2021
- Cardiolipin deficiency in Barth syndrome is not associated with increased superoxide/H2O2 production in heart and skeletal muscle mitochondriaFEBS Letters, 2020
- Barth syndrome cardiomyopathy: targeting the mitochondria with elamipretideHeart Failure Reviews, 2020
- AMPK and TOR: The Yin and Yang of Cellular Nutrient Sensing and Growth ControlCell Metabolism, 2020
- Mitochondrial dysfunctions in barth syndromeIUBMB Life, 2019
- Muscle-derived autologous mitochondrial transplantation: A novel strategy for treating cerebral ischemic injuryBehavioural Brain Research, 2019
- Barth syndrome: Cellular compensation of mitochondrial dysfunction and apoptosis inhibition due to changes in cardiolipin remodeling linked to tafazzin (TAZ) gene mutationBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2013
- Defective Remodeling of Cardiolipin and Phosphatidylglycerol in Barth SyndromeBiochemical and Biophysical Research Communications, 2000
- An X-linked mitochondrial disease affecting cardiac muscle, skeletal muscle and neutrophil leucocytesJournal of the Neurological Sciences, 1983